Comparative evaluation of oxidative stress biomarkers F2-isoprostanes and 8-OHdG in Parkinson's disease and Type 2 Diabetes Mellitus: a systematic review and meta-analysis of human studies.
This systematic review/meta-analysis of 54 human studies finds both F2-isoprostanes and 8-OHdG markedly elevated in T2DM, but only 8-OHdG is moderately elevated in Parkinson's disease, indicating DNA oxidative damage rather than lipid peroxidation may better reflect oxidative stress in PD and…
What the AI sees
This systematic review/meta-analysis of 54 human studies finds both F2-isoprostanes and 8-OHdG markedly elevated in T2DM, but only 8-OHdG is moderately elevated in Parkinson's disease, indicating DNA oxidative damage rather than lipid peroxidation may better reflect oxidative stress in PD and…
Research significance
Identifies 8-OHdG as a more promising biomarker for PD patient stratification and target‑engagement in trials and argues for standardized, multi-compartment and longitudinal biomarker studies to de-risk antioxidant-focused therapeutic development.
Source abstract
BACKGROUND: Oxidative stress is central to type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD). However, the utility of biomarkers for lipid peroxidation (F2-isoprostanes) and DNA damage (8-OHdG) in the comorbidity of PD and T2DM remains unclear. METHODS: We conducted a systematic review and meta-analysis of 54 unique studies of human subjects aged ≥ 50 years (n = 7,521: 3,522 with T2DM, 722 with PD, and 3,277 controls), measuring biomarkers in serum, plasma, or leukocytes. Mixed-effects models quantified standardized differences (Hedges' g) across subgroups. RESULTS: In T2DM, F2-isoprostanes (g = 1.60, 95% CI: 0.95-2.25) and 8-OHdG (g = 2.64, 95% CI: 2.13-3.14) were markedly elevated (p < 0.001). Stronger effects were observed in younger cohorts and serum/plasma samples, with complications like nephropathy exhibiting extreme oxidative stress (g = 5.24). In PD, 8-OHdG was moderately elevated (g = 0.78, 95% CI: 0.18-1.39; p = 0.011), particularly in randomized controlled trials and plasma samples, whereas F2-isoprostanes were not significantly elevated (g = 0.47, 95% CI: -0.43-1.38). High heterogeneity in T2DM (I2 > 90%) reflected methodological variability. CONCLUSION: Distinct profiles - both markers elevated in T2DM but only 8-OHdG in PD - underscore 8-OHdG's potential in PD-T2DM comorbidity. Future research should focus on standardized assays, multi-compartmental or multi-modal sampling, and longitudinal studies to clarify mechanisms and therapeutic targets.